🔄 Updated 2026 — Reviewed and refreshed with the latest research.
Quick Summary
- CJC-1295 without DAC (Mod GRF 1-29): 30-min half-life, pulsatile GH, multiple daily injections, optimal for most goals
- CJC-1295 with DAC: 6-8 day half-life, continuous GH bleed, once/twice weekly — receptor downregulation risk
- Primary mechanism: GHRH receptor agonism → GH release from pituitary
- Tony’s position: Mod GRF 1-29 + ipamorelin for pulsatile physiology is superior
- DAC has a place: compliance situations, older individuals with blunted GH pulses
The cjc-1295 dac question isn’t just marketing — it fundamentally changes the pharmacology and therefore your results. DAC (Drug Affinity Complex) is a lysine-maleimidoproprionic acid group that lets the peptide bind albumin in the bloodstream, dramatically extending half-life from 30 minutes to 6-8 days. That sounds like a convenience win. It’s not that simple.
Mod GRF 1-29 (CJC Without DAC)
- Half-life: 30 minutes
- GH pattern: Sharp physiological pulse matching natural GH rhythm
- Dosing: 2-3x daily injections required
- GHRP synergy: Excellent — available at the exact moment ipamorelin triggers the pulse
CJC-1295 With DAC
- Half-life: 6-8 days
- GH pattern: Continuous “GH bleed” — non-pulsatile elevation
- Dosing: Once or twice weekly
- Receptor risk: Chronic non-pulsatile stimulation → GHRH receptor downregulation
The tony huge laws of biochemistry physics — Law 4: Self-Regulating Systems
This is Law 4 of the tony huge Laws of Biochemistry Physics in action: the body fights to maintain homeostasis. Your GHRH receptor system evolved for pulsatile stimulation — peaks and troughs. Constant stimulation from CJC with DAC triggers receptor downregulation, gradually diminishing the response. Mod GRF 1-29 works WITH the pulsatile design of your GH axis rather than fighting against it. The self-regulating system stays sensitive and responsive long-term.
Head-to-Head Comparison
| Factor | Mod GRF 1-29 | CJC-1295 with DAC |
|---|---|---|
| GH Pattern | Pulsatile (physiological) | Continuous (non-physiological) |
| Receptor Sensitivity | Preserved long-term | Downregulation risk |
| GHRP Synergy | Excellent | Reduced (timing mismatch) |
| Convenience | Multiple daily injections | 1-2x weekly |
| IGF-1 Response | Higher peaks | Steady but lower peaks |
Recommended Protocol
- Mod GRF 1-29: 100-200 mcg per injection, combined with ipamorelin 100-300 mcg
- Same syringe, 2-3x daily: fasted morning, and before sleep
- Fasted window: 30-60 min before and after — insulin blunts GH release
- Monitoring: IGF-1 at 4-6 weeks (expect 30-50% increase), fasting glucose quarterly
References
- Jetté L et al. “hGH-releasing peptide 2 stimulates the gh/IGF-1 axis.” Endocrinology, 2005.
- Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone.” Endocr Rev, 2006.
See the complete GH optimization guide at Enhanced Athlete Protocol Peptides and Bloodwork Monitoring.